Weekly Epirubicin for Hormone-Resistant Prostate Cancer
Author Information
Author(s): Petrioli R, Fiaschi A I, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G
Primary Institution: University of Siena, Siena, Italy
Hypothesis
Does weekly epirubicin improve outcomes in patients with metastatic hormone-resistant prostate cancer?
Conclusion
Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result, improving quality of life and survival in patients with metastatic hormone-resistant prostate cancer.
Supporting Evidence
- 44% of evaluable patients showed a palliative response after six treatment cycles.
- 56% of evaluable patients showed a palliative response after twelve treatment cycles.
- The median duration of the palliative response was 9 months.
- Quality of life improved in 52% of patients after six cycles and in 68% after twelve cycles.
- 12- and 18-month survival rates were 56% and 31%, respectively.
Takeaway
This study tested a medicine called epirubicin to help men with a tough kind of prostate cancer feel better and live longer. It worked for many of them!
Methodology
148 patients received weekly intravenous infusions of epirubicin, and their pain, quality of life, and survival were monitored.
Potential Biases
Potential biases due to non-randomized design and patient selection criteria.
Limitations
The study was not randomized, and compliance with quality of life assessments decreased over time.
Participant Demographics
Median age was 67 years, with 142 patients having bone metastases.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website